Chronix Biomedical reports positive interim pancreatic cancer data

Chronix Biomedical reports a positive interim analysis of its ongoing validation study of its Copy Number Instability (CNI)-based therapeutic monitoring test in pancreatic cancer. The study compares the accuracy of Chronix’s CNI-based test at predicting a clinical response, as early as after the first cycle of chemotherapy compared to CA19-9, a commonly used biomarker.

By |2019-03-21T09:37:57+00:00June 14th, 2017|Chronix news|0 Comments

Chronix at the ASCO 2017 Annual Meeting

Chronix Biomedical

This is the third year that Chronix is presenting its study results at ASCO — this year’s results are from a blinded prospective study validating the use of a CNI Monitor blood test to predict the treatment outcome of patients undergoing immunotherapy.

By |2019-03-21T09:37:57+00:00June 2nd, 2017|Chronix news|0 Comments